The rise of the genome and personalised medicine
- Helen K Brittain, honorary clinical fellow in clinical geneticsA⇑,
- Richard Scott, consultant in clinical geneticsB and
- Ellen Thomas, honorary consultant in clinical geneticsC
- AGreat Ormond Street Hospital, London, UK, Queen Mary University of London, UK and Genomics England, London, UK
- BGreat Ormond Street Hospital, London, UK and Genomics England, London, UK
- CGuy’s and St Thomas’ NHS Foundation Trust, London, UK, Queen Mary University of London, UK and Genomics England, London, UK
- Address for correspondence: Dr Helen Brittain, Clinical Genetics, Great Ormond Street Hospital For Children NHS Trust, Level 4, Barclay House, Great Ormond Street, London WC1N 3JH, UK. Email: helen.brittain{at}genomicsengland.co.uk
Abstract
Virtually all medical specialties are impacted by genetic disease. Enhanced understanding of the role of genetics in human disease, coupled with rapid advancement in sequencing technology, is transforming the speed of diagnosis for patients and providing increasing opportunities to tailor management. As set out in the Annual report of the Chief Medical Officer 2016: Generation Genome1 and the recent NHS England board paper Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments,2 the increasing ‘mainstreaming’ of genetic testing into routine practice and plans to embed whole genome sequencing in the NHS mean that the profile and importance of genomics is on the rise for many clinicians. This article provides a brief overview of genomics and its current clinical applications, including its contribution to personalised medicine. Physicians will be signposted to key issues that will allow the successful implementation of genomics for rare disease diagnosis and cancer management.
- © Royal College of Physicians 2017. All rights reserved.
